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Background: Osteoarthritis (OA) knee pain is common in older patients and contributes to decreased quality of life.
Older patients are generally at higher risk of adverse drug reactions due to age-related changes in physiology that
affect drug disposition, metabolism, and response. These analyses examined efficacy and safety outcomes of older
(≥65 years) versus younger patients from clinical trials of duloxetine in the management of OA knee pain.
Methods: This is a post hoc analysis of two 13-week studies, in which patients were randomized to duloxetine 60
mg/day or placebo. Both studies allowed potential dose changes after 7 weeks of dosing, with Study I re-randomizing
duloxetine treated patients to either stay on 60 mg/day or increase to 120 mg/day; while Study II more closely
mimicked clinical practice by escalating only non-responding patients to 120 mg/day. For all analyses patients were
subgrouped by age: older (≥65 years) and younger (40–64 years). Overall efficacy and safety age-group comparisons of
duloxetine versus placebo were performed using pooled data from both studies with all duloxetine dose levels
combined. Safety analyses included discontinuation rates, treatment-emergent adverse events, and serious adverse
events. To evaluate the effects of increasing the dose in non-responding patients, only Study II data were evaluated.
Treatment arms were defined post hoc as placebo, duloxetine 60 mg/day, and duloxetine 60/120 mg/day.
Results: At study end, patients in each age group who were treated with duloxetine versus placebo had
significantly greater improvement in pain (both, p<.05), and there was no significant effect of age on treatment
(p=.72). Increasing the dose to 120 mg in non-responding patients was not found to have a significant advantage.
Among treatment-emergent adverse events with duloxetine treatment, only dizziness had a significantly
differential treatment effect (p=.02) with greater incidence over placebo in younger patients (6.6% versus 0.6%,
p=.02), but not in older patients (1.0% versus 3.2%, p=.29).
Conclusions: Duloxetine was efficacious and generally well tolerated for management of symptomatic knee OA in
both older and younger patients, but increasing the dose to 120 mg in non-responding patients did not provide
additional benefit.
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Osteoarthritis (OA) of the knee is the most common
form of arthritis in older individuals and a leading cause
of pain and disability [1], which contributes to overall
decreased quality of life, [2] as well as the increased risk
of depression and anxiety [3,4]. Alleviation of pain symp-
toms is paramount in managing knee OA, and should be
the focus of treatment [5]. The approach to pain manage-
ment in older patients may differ from that for younger
patients, due to generally higher risk of adverse drug reac-
tions from age-related changes in physiology that affect
drug disposition, metabolism, and response [6]. Since
many adverse events are dose related, appropriate dosing
for analgesic medications in this sensitive population is a
particularly important clinical concern.
Prescription pain management options for OA knee pain
include topical or oral non-steroidal anti-inflammatory
drugs (NSAIDs), intra-articular injections of corticoste-
roids and hyaluronates, and opioids [5]. NSAIDs and
opioids are associated with potential use-limiting risks
or side effects which may be heightened in the older pa-
tient [7]. These effects include gastrointestinal bleeding,
peptic ulcer disease, nephrotoxicity, and serious long
term cardiovascular effects with NSAID use, and risks
of sedation, respiratory depression, overdose, misuse, or
dependency with opioids [7]. When treating OA knee
pain in older patients, it is important to have alternative
treatment options that offer efficacy with an acceptable
risk profile in this population.
Current evidence-based literature addressing the phar-
macological management of chronic pain in older persons
is sparse [8]. As a result, algorithms for treatment are
mostly generated from study outcomes in younger pa-
tients that are extrapolated to older individuals. Since
clinical trials in OA knee pain often include patients
ranging in age from 40 years to 65 years and older, ana-
lyzing treatment outcomes in age-stratified data may
provide better clinical insight than extrapolations from
younger to older patients.
In clinical studies, duloxetine (a selective, relatively
balanced serotonin and norepinephrine reuptake inhibitor)
has demonstrated efficacy in four distinct chronic pain
conditions: diabetic peripheral neuropathic pain [9,10],
fibromyalgia [11,12], chronic low back pain [13,14], and
OA knee pain [15,16]. Since the OA knee pain trials in-
cluded many older patients, we conducted a post hoc ana-
lysis of those trials to examine any differential effect of age
on the efficacy and safety of duloxetine. In addition, we ex-
amined data that might suggest appropriate dosing of
duloxetine in this population. In a recently published study,
Abou-Raya et al. [17] reported that duloxetine 60 mg/day
significantly improved pain as compared with placebo in
older patients with OA knee pain, many of whom also had
comorbid depression. Our post hoc analysis differs fromthat study in that the patients in our studies were not
depressed, thereby allowing determination of the direct
analgesic effect of duloxetine without confounding by
improvement in depression. Furthermore, we compared
treatment outcomes between older and younger pa-
tients, and investigated the utility of increasing the dose
in non-responding patients.
Methods
Data were from two published 13-week, randomized,
placebo-controlled studies in male and female outpatients
who were at least 40 years of age, and met American
College of Rheumatology clinical and radiographic criteria
for the diagnosis of OA of the knee [15,16]. In both stud-
ies, pain was assessed daily using an ordinal 11-point nu-
merical rating scale (0 to 10) that was recorded in patient
diaries. Efficacy assessments were based on the weekly
mean of the daily average pain severity from these patient
diaries. Pain was also assessed with the Brief Pain Inven-
tory (BPI) [18] (severity range: 0–10) at weeks 4, 7, and
13. All patients provided written informed consent before
the commencement of any study procedures.
For both studies, patients were required to have pain
for ≥14 days of each month for 3 months prior to study
entry, with a mean pain severity ≥4 on daily pain diary
ratings during the screening and baseline periods. In
addition, patients had to agree to maintain their usual
activity level throughout the course of the study. Key
exclusion criteria for both studies included having a
body mass index >40 kg/m2; a diagnosis of inflammatory
arthritis or an autoimmune disorder; having received
invasive therapies within the prior 3 months, or joint re-
placement to the knee; being non-ambulatory or needing
assistance walking with crutches or walker; any serious
medical condition or psychiatric disorder, including major
depressive disorder, as identified by the Mini International
Neuropsychiatric Interview [19] that could compromise
participation in the study.
Patients were randomly assigned 1:1 in double-blind
fashion to treatment with duloxetine 60 mg/day or
placebo as determined by a computer-generated ran-
dom sequence using an Interactive Voice Response
System (IVRS). All patients randomized to duloxetine
were started on 30 mg/day for one week then escalated
to 60 mg/day. After 7 weeks, the duloxetine dosing regi-
men could change. In Study I [15], patients in the
duloxetine group were re-randomized via IVRS without
regards to change in pain severity to either continue
duloxetine 60 mg/day or to have their dose increased
directly to 120 mg/day, and were continued on that dose
for the remainder of the study. In Study II [16], patients
in the duloxetine group who had <30% reduction from
baseline in pain severity on the BPI 24-h average pain
severity scale, had their dose increased directly to
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der of the study.
For this post hoc analysis, two patient groups were de-
fined by their age at study entry: older patients were at
least 65 years of age, and younger patients were less than
65. For the efficacy and safety analyses comparing
duloxetine with placebo within age groups, studies were
pooled and doses were pooled. In addition, a subgroup
analysis was conducted to determine the efficacy of
duloxetine in the “oldest of the old” (>75 years) as com-
pared with the “younger of the old” (65 to <75 years) pa-
tients. For comparing the effect of increasing duloxetine
to 120 mg in non-responding patients, only data from
Study II were evaluated as it most closely reflected clin-
ical practice; whereas re-randomization to a higher dose
does not. Treatment arms were defined post hoc as pla-
cebo, duloxetine 60 mg/day (patients who remained on
60 mg for the entire study), and duloxetine 60/120 mg/
day (patients who received 60 mg for 7 weeks, followed
by duloxetine 120 mg for 6 weeks). Safety assessments
included spontaneously reported treatment-emergent ad-
verse events (TEAEs), discontinuation rates due to TEAEs,
serious adverse events (SAEs), and treatment-emergent ab-
normal vital signs.
Categorical baseline characteristics were compared be-
tween age groups using a logistic regression model with
terms for study, treatment, age group and the treatment-
by-age group interaction. Quantitative baseline charac-
teristics were compared using an analysis of variance
model with similar explanatory terms. Weekly means of
change from baseline in the average pain severity ratings
from patient diaries were analyzed using a likelihood-based,
mixed-effects model repeated measures (MMRM) ap-
proach that used all available observations. The model
included the fixed categorical effects of site, treatment,
week, age group, treatment-by-week interaction, age group-
by-week interaction, treatment-by-age group interaction,Table 1 Baseline demographics and illness characteristics
Older
Variable Placebo N=94 Duloxetine N=103
Age in years, mean (SD) 72.0 (4.0) 71.4 (4.1)
Female, n (%) 72 (76.6) 61 (59.2)
Caucasian, n (%) 88 (93.6) 97 (94.2)
OA duration, years, mean (SD) 8.1 (8.1) 7.9 (8.3)
OA pain, years. mean (SD) 9.4 (8.1) 10.3 (9.1)
BMI (kg/m2), mean (SD) 30.0 (4.6) 30.1 (4.1)
Pain diary ratings, mean (SD) 6.2 (1.4) 6.0 (1.3)
BPI, mean (SD) 6.3 (1.5) 6.0 (1.6)
NSAID use, n (%)a 39 (41.5) 37 (35.9)
aNSAID use was >14 days/month. Abbreviations: SD, standard deviation; OA, osteoa
anti-inflammatory drug.treatment-by-age-group-by-week interaction, as well as the
continuous fixed covariates of baseline score and baseline-
by-week interaction.
The analysis of completion rates, discontinuation rates
due to adverse events (AEs), and incidence of spontan-
eously reported TEAEs and SAEs were compared using
a logistic regression model with terms for study, treat-
ment, age category, and the treatment-by-age inter-
action. For comparison among treatment groups and
age groups, test results were considered statistically sig-
nificant if p≤.05; for tests of interaction, results were
considered statistically significant if p≤.1. Statistical ana-
lyses were performed using SAS, version 9.1 (SAS Insti-
tute, Inc, Cary, NC).
Results
Demographic characteristics and baseline pain severity
of patients stratified according to age group and treat-
ment arms are summarized in Table 1. The mean age of
the older patients (n=197) was 72 (range, 65 to 87)
years; 67.5% were female, and 93.9% were Caucasian.
The mean age of the younger patients (n=290) was 56
(range, 40 to 64) years; 73.8% were female; and 89.3%
were Caucasian. Most of the patients in each age group
were overweight or obese, and the mean BMI at baseline
did not differ between treatments or age groups. The
duration of OA since diagnosis was significantly longer
in the older versus the younger group (p<.001); as was
the duration of OA pain since onset (p<.001). NSAID
use >14 days/month was significantly less in the older
group versus the younger group (p=.03). Differences be-
tween age groups in baseline pain diary scores or BPI
average pain severity were not significant.
Over the course of 13-weeks of treatment, both older
and younger patients experienced significantly greater
pain reduction each week with duloxetine treatment
versus placebo (Figure 1). No statistically significantYounger Older versus younger
Placebo N=154 Duloxetine N=136 p values
56.2 (5.7) 56.0 (5.8) <.001
116 (75.3) 98 (72.1) .19
136 (88.3) 123 (90.4) .11
5.3 (5.5) 5.5 (6.0) <.001
7.1 (7.1) 7.2 (7.2) <.001
30.9 (4.9) 29.9 (5.0) .45
6.1 (1.2) 6.1 (1.2) .56
6.1 (1.4) 6.2 (1.4) .83
73 (47.4) 68 (50.0) .03






























































† * * † † † *
* p≤.05, † p≤.01, ‡p≤.001
Week-by-treatment-by-age group interaction, p=.72
Figure 1 Mean change from baseline in weekly average daily pain diary scores in older and younger patients treated with duloxetine
60/120 mg/day or placebo from pooled study data.
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tients was seen across weeks (age group- by-week-by
treatment interaction p-value= 0.72). Among the older
patients, there was no significant difference in efficacy
between those who were >75 years and those who were
<75 years (p=.70). The effect of increasing the dose in
non-responding patients was not associated with signifi-
cant pain reduction versus placebo in subsequent weeks
or at endpoint (Figure 2).
Study completion rates did not differ between age
groups (p=.69), but significantly more patients treated
with placebo versus duloxetine completed the study (older,

































































Figure 2 Mean change from baseline in weekly average daily pain dia
with duloxetine 60 mg/day and remained on that dose; those who w
those who received placebo.There was no significant treatment-by-age group inter-
action in rates of discontinuation due to adverse events
(p=.74), but the rate was significantly greater in patients
treated with duloxetine versus placebo (older, 22.3% ver-
sus 7.5%; younger, 11.8% versus 4.5%; p<.001), and was
significantly greater in older versus younger patients
(p=.05). AEs that were reasons for discontinuation in the
older group treated with duloxetine included: arthralgia
(n=2), asthenia (n=3), nausea (n=4), and one incident for
each of these: abnormal dreams, anxiety, bronchitis,
diarrhea, drug intolerance, ejaculation disorder, erectile
dysfunction, flatulence, headache, hypercreatinemia, in-
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Group Interaction p values
Patients with at least one TEAE 40(42.6) 55(53.4) 51 (33.1) 65(47.8) .66a
Constipation 2 (2.1) 11 (10.7) 0 (0) 3 (2.2) 1.00b
Diarrhea 2 (2.1) 4 (3.9) 4 (2.6) 7 (5.1) .93
Dizziness 3 (3.2) 1 (1.0) 1 (0.6) 9 (6.6) .02
Nausea 3 (3.2) 9 (8.7) 2 (1.3) 11 (8.1) .40c
Somnolence 3 (3.2) 6 (5.8) 1 (0.6) 4 (2.9) .49
Patients with at least one SAE 2 (2.1) 3 (2.9) 2 (1.3) 1 (0.7) .57
a treatment effect, p=.005.
b treatment effect, p=.03.
c treatment effect, p=.004.
Abbreviations: TEAE, treatment-emergent adverse event; SAE, serious adverse event.
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discontinued due to nausea (n=3), and n=1 for each of the
following: anxiety, condition aggravated, constipation, diz-
ziness, dyspepsia, fatigue, hemorrhoids, hot flush, insom-
nia, memory impairment, palpitations, sleep disorder, and
somnolence.
TEAEs that occurred with a frequency of ≥5% are
summarized in Table 2. Overall, there was no significant
treatment-by-age group interaction for the occurrence of
at least one TEAE, but within both age groups duloxetine
treatment was associated with significantly greater fre-
quency of experiencing at least one TEAE of any type, as
well as a greater frequency of patients experiencing consti-
pation and nausea. Of the individual TEAEs, dizziness
showed a significant treatment-by-age group interaction
with duloxetine treatment, with greater incidence than
placebo in younger patients but not in the older patients.
Rates of TEAEs that occurred after patients were escalatedTable 3 Treatment-emergent vital sign abnormalities
Older
N* Placebo n (%) N* Duloxetine n (%)
PCS Weight gain 92 3 (3.3) 102 0
PCS Weight loss 92 0 102 6 (5.9)
Sustained hypertension 84 2 (2.4) 95 1 (1.1)
Diastolic hypertension 82 0 91 0
Systolic hypertension 63 2 (3.2) 78 1 (1.3)
Orthostatic hypotension 82 8 (9.8) 98 13 (13.3)
Orthostatic tachycardia 93 0 102 0
a Treatment-by-age group interaction could not be calculated for diastolic hyperten
were 0% values in one or more treatment groups and the model could not fit the d
Definitions: N*, number of patients at baseline who did not have the abnormality b
increase in body weight. PCS (potentially clinically significant) weight loss is ≥5% de
pressure ≥ 85 mm Hg and increase from baseline of 10 mm Hg for at least 3 conse
Hg and an increase from baseline of 10 mm Hg for at least 3 consecutive visits. Sus
least 3 consecutive visits. Orthostatic hypotension is a decrease of at least 10 mm H
pressure at least 20 mm Hg less than the supine systolic blood pressure. Orthostatito duloxetine 120 mg were numerically higher in the
younger patients as observed in the older ones (24.4%
versus 20%), and these rates were also numerically
higher than those observed in patients who remained
on the 60 mg dose (14.6% in older and 14.9% in younger
patients).
The frequency of SAEs did not differ significantly
between age or treatment groups and there was no
significant treatment-by-age interaction (Table 2). SAEs
reported by older patients who received duloxetine (n=1
for each) included: asthma, bronchitis, drug intolerance,
rhinitis allergic, and supraventricular tachycardia. Older
patients in the placebo group reported atrial fibrillation
(n=1), and myocardial infarction (n=1). SAEs in younger
patients treated with duloxetine included memory im-
pairment (n=1), younger patients treated with placebo
reported dehydration (n=1) and gouty arthritis (n=1).
There were no SAEs that occurred in either older orYounger
N* Placebo n (%) N* Duloxetine n (%) Treatment-by-Age
Group Interaction
p values
153 0 128 1 (0.8) ‐‐‐ a
153 1 (0.7) 128 2 (1.6) ‐‐‐ a
140 2 (1.4) 121 3 (2.5) .37
135 1 (0.4) 116 0 ‐‐‐ a
124 2 (1.6) 110 3 (2.7) .34
150 8 (5.3) 128 13 (10.2) .60
152 1 (0.7) 136 0 ‐‐‐ a
sion, PCS weight gain or loss; or for orthostatic tachycardia, because there
ata.
eing summarized. PCS (potentially clinically significant) weight gain is ≥7%
crease in body weight. Diastolic hypertension is sitting diastolic blood
cutive visits. Systolic hypertension is sitting systolic blood pressure ≥ 140 mm
tained hypertension is having both diastolic and systolic hypertension for at
g less than the supine diastolic blood pressure or the standing systolic blood
c tachycardia is increase of ≥100 beats per minute.
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duloxetine. No deaths occurred in either study.
Treatment-emergent vital sign abnormalities are sum-
marized in Table 3. Across age groups and treatment
groups, the most common abnormality was orthostatic
hypotension. There were no significant differences between
age groups, and no statistically significant treatment-by
-age-by-visit interactions on treatment-emergent abnor-
malities in vital signs or weight.
Discussion
This post hoc analysis did not find a differential effect of
age on duloxetine treatment in non-depressed patients
with OA knee pain. This is an important finding as it
suggests that duloxetine is efficacious in the treatment
of OA knee pain regardless of age. The lack of an age ef-
fect on pain reduction in this patient population is sup-
ported by similar findings in a post hoc age-stratified
subgroup analysis of duloxetine in the treatment of dia-
betic peripheral neuropathic pain [20].
In both older and younger patients, treatment with
duloxetine 60 mg/day was associated with significantly
greater pain reduction as compared to placebo. However,
increasing the dose of duloxetine in older and younger
patients, who were not experiencing adequate pain reduc-
tion, was not found to provide additional benefit. These
findings may be particularly relevant to the treatment of
older patients to avoid unnecessary dose escalation.
Overall, duloxetine was generally well tolerated by pa-
tients in each age group, considering that rates of com-
pletion and discontinuation due to adverse events did
not differ significantly or show a tendency toward more
drop outs in the older population, and were similar to
findings in other studies across indications. Further,
adverse events with duloxetine generally did not differ
between age groups except that dizziness was associated
with greater risk among younger patients relative to older
ones. While orthostatic hypotension was the most com-
mon treatment-emergent vital sign abnormality reported
in each age and treatment group, there was no significant
treatment-by-age group interaction.
The interpretation of this post hoc analysis has limita-
tions to be considered. First, neither study was specific-
ally designed to assess safety or efficacy in exclusively
older patients. Furthermore, the results of subgroup ana-
lyses should generally be interpreted with caution due to
concerns about multiple testing and increased likelihood
of finding potentially spurious and un-reproducible re-
sults [21].
Conclusions
Duloxetine 60 mg was efficacious for managing OA knee
pain in both age groups, but increasing the dose to
120 mg in non-responding patients did not provideadditional benefit. There was no consistent signal indi-
cating that the safety of duloxetine might differ signifi-
cantly between older and younger patients.
Competing interests
This work was supported by Lilly USA, LLC, Indianapolis, IN, USA.
JLM is on the speaker's bureau and advisory board for Eli Lilly and Company.
DR, JA, and MMW are employees and stockholders of Eli Lilly and Company.
Authors’ contributions
JLM contributed to interpretation of the data and critical review of the
manuscript. DR contributed to study design, interpretation of the data, and
critical review of the manuscript. JA prepared the manuscript and
contributed to interpretation of the data. MMW contributed to study design,
interpretation of the data, and critical review of the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
Presented at the American College of Rheumatology ACR/ARHP annual
scientific sessions; Chicago, IL, USA; November 5–9, 2011.
Author details
1Patient Centered Healthcare, Atlanta, GA, USA. 2Lilly USA, LLC, Drop Code
4133, Indianapolis, IN 46285, USA.
Received: 28 November 2012 Accepted: 12 April 2013
Published: 17 April 2013
References
1. Lawrence RC, Helmick CG, Arnett FC, Felson DT, Giannini EH, Heyse SP,
Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer ST, Steen VD, Wolf
F: Estimates of the prevalence of arthritis and selected musculoskeletal
disorders in the United States. Arthritis Rheum 1998, 41:778–799.
2. Skevington SM: Investigating the relationship between pain and discomfort
and quality of life, using the WHO-QOL. Pain 1998, 76:395–406.
3. Axford J, Heron C, Ross F, Victor CR: Management of knee osteoarthritis in
primary care: pain and depression are the major obstacles. J Psychosom
Res 2008, 64:461–467.
4. Bair MJ, Wu J, Damush TM, Sutherland JM, Kroenke K: Association of
depression and anxiety alone and in combination with chronic
musculoskeletal pain in primary care patients. Psychosom Med 2008,
70(8):890–897.
5. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-
Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M,
Hunter DJ, Kwoh K, Lohmander LS, Tugwell P: OARSI recommendations for
the management of hip and knee osteoarthritis, Part II: OARSI evidence-
based, expert consensus guidelines. Osteoarthr Cartilage 2008, 16:137–162.
6. Fine PG: Pharmacological management of persistent pain in older
patients. Clin J Pain 2004, 20:220–226.
7. Fitzcharles MA, Lussier D, Shir Y: Management of chronic arthritis pain in
the elderly. Drugs Aging 2010, 27:471–490.
8. Ickowicz E: Pharmacological management of persistent pain in older
persons. J Am Geriatr Soc 2009, 57:1331–1346.
9. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S,
Wernicke JF: A double-blind, randomized multicenter trial comparing
duloxetine with placebo in the management of diabetic peripheral
neuropathic pain. Pain Med 2005, 6:346–356.
10. Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, Raskin
J: A randomized controlled trial of duloxetine in diabetic peripheral
neuropathic pain. Neurology 2006, 67:1411–1420.
11. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein
DJ: A double-blind, multicenter trial comparing duloxetine with placebo
in the treatment of fibromyalgia patients with or without major
depressive disorder. Arthritis Rheum 2004, 50:2974–2984.
12. Russell JI, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker
DJ, Chappell AS, Arnold LM: Efficacy and safety of duloxetine for
treatment of fibromyalgia in patients with or without major depressive
disorder: Results from a 6-month, randomized, double-blind, placebo-
controlled, fixed-dose trial. Pain 2008, 136:432–444.
13. Skljarevski V, Ossanna MJ, Liu-Seifert H, Zhang Q, Chappell A, Iyengar S,
Detke M, Backonja M: A double-blind, randomized trial of duloxetine
Micca et al. BMC Musculoskeletal Disorders 2013, 14:137 Page 7 of 7
http://www.biomedcentral.com/1471-2474/14/137versus placebo in the management of chronic low back pain. Eur J
Neurol 2009, 16:1041–1048.
14. Skljarevski V, Zhang S, Desaiah D, Alaka KJ, Palacios S, Miazgowski T, Patrick
K: Duloxetine versus placebo in patients with chronic low back pain: a
12-week, fixed dose, randomized, double-blind trial. J Pain 2010,
11(12):1282–1290.
15. Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V, Li LC,
Bennett RM, Collins H: Duloxetine, a centrally acting analgesic, in the
treatment of patients with osteoarthritis knee pain: a 13-week,
randomized, placebo-controlled trial. Pain 2009, 146:253–260.
16. Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V, Belenkov Y,
Brown JP: A double-blind, randomized, placebo-controlled study of the
efficacy and safety of duloxetine for the treatment chronic pain due to
osteoarthritis of the knee. Pain Pract 2011, 11(1):33–41.
17. Abou-Raya S, Abou-Raya A, Helmi M: Duloxetine for the management of
pain in older adults with knee osteoarthritis: randomised placebo-
controlled trial. Age Aging 2012, 41(5):646–652.
18. Cleeland CS, Ryan KM: Pain assessment: global use of the brief inventory.
Ann Acad Med Singapore 1994, 23:129–138.
19. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E,
Herqueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric
Interview (M.I.N.I.): the development and validation of a structured
diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry
1998, 59(Suppl 20):22–33.
20. Wasan AD, Ossanna MJ, Raskin J, Wernicke JF, Robinson MJ, Hall JA,
Edwards SE, Lipsius S, Meyers AL, McCarberg BH: Safety and efficacy of
duloxetine in the treatment of diabetic peripheral neuropathic pain in
older patients. Curr Drug Saf 2009, 4:22–29.
21. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM: Statistics in
medicine – reporting of subgroup analyses in clinical trials. N Engl J
Med 2007, 357:2189–2194.
doi:10.1186/1471-2474-14-137
Cite this article as: Micca et al.: Safety and efficacy of duloxetine
treatment in older and younger patients with osteoarthritis knee pain: a
post hoc, subgroup analysis of two randomized, placebo-controlled
trials. BMC Musculoskeletal Disorders 2013 14:137.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
